CN110650953A - 一种穿心莲内酯改构化合物的盐型、晶型及其制备方法 - Google Patents

一种穿心莲内酯改构化合物的盐型、晶型及其制备方法 Download PDF

Info

Publication number
CN110650953A
CN110650953A CN201880033723.8A CN201880033723A CN110650953A CN 110650953 A CN110650953 A CN 110650953A CN 201880033723 A CN201880033723 A CN 201880033723A CN 110650953 A CN110650953 A CN 110650953A
Authority
CN
China
Prior art keywords
compound
formula
minus
plus
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880033723.8A
Other languages
English (en)
Other versions
CN110650953B (zh
Inventor
夏建华
江志赶
贺海鹰
王静
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NANJING MINGDE NEW DRUG RESEARCH AND DEVELOPMENT Co Ltd
HEILONGJIANG ZBD PHARMACEUTICAL CO Ltd
Original Assignee
NANJING MINGDE NEW DRUG RESEARCH AND DEVELOPMENT Co Ltd
HEILONGJIANG ZBD PHARMACEUTICAL CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NANJING MINGDE NEW DRUG RESEARCH AND DEVELOPMENT Co Ltd, HEILONGJIANG ZBD PHARMACEUTICAL CO Ltd filed Critical NANJING MINGDE NEW DRUG RESEARCH AND DEVELOPMENT Co Ltd
Publication of CN110650953A publication Critical patent/CN110650953A/zh
Application granted granted Critical
Publication of CN110650953B publication Critical patent/CN110650953B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

本发明公开了穿心莲内酯改构化合物的盐型、晶型、制备方法及其医药用途。

Description

PCT国内申请，说明书已公开。

Claims (15)

  1. PCT国内申请，权利要求书已公开。
CN201880033723.8A 2017-05-24 2018-05-24 一种穿心莲内酯改构化合物的盐型、晶型及其制备方法 Active CN110650953B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2017103735766 2017-05-24
CN201710373576 2017-05-24
PCT/CN2018/088168 WO2018214929A1 (zh) 2017-05-24 2018-05-24 一种穿心莲内酯改构化合物的盐型、晶型及其制备方法

Publications (2)

Publication Number Publication Date
CN110650953A true CN110650953A (zh) 2020-01-03
CN110650953B CN110650953B (zh) 2023-01-10

Family

ID=64396260

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880033723.8A Active CN110650953B (zh) 2017-05-24 2018-05-24 一种穿心莲内酯改构化合物的盐型、晶型及其制备方法

Country Status (6)

Country Link
US (1) US11299482B2 (zh)
EP (1) EP3632909B1 (zh)
CN (1) CN110650953B (zh)
ES (1) ES2955294T3 (zh)
PT (1) PT3632909T (zh)
WO (1) WO2018214929A1 (zh)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105367558A (zh) * 2015-08-27 2016-03-02 沈阳药科大学 穿心莲内酯衍生物及其制备方法和用途
CN106800551A (zh) * 2015-11-26 2017-06-06 南京明德新药研发股份有限公司 穿心莲内酯改构化合物
US20170354639A1 (en) * 2014-10-24 2017-12-14 Biogen Ma Inc. Diterpenoid derivatives and methods of use thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3381912A4 (en) * 2015-11-26 2019-01-09 Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. MODIFIED COMPOUND OF ANDROGRAPHOLIDE

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170354639A1 (en) * 2014-10-24 2017-12-14 Biogen Ma Inc. Diterpenoid derivatives and methods of use thereof
CN105367558A (zh) * 2015-08-27 2016-03-02 沈阳药科大学 穿心莲内酯衍生物及其制备方法和用途
CN106800551A (zh) * 2015-11-26 2017-06-06 南京明德新药研发股份有限公司 穿心莲内酯改构化合物

Also Published As

Publication number Publication date
EP3632909B1 (en) 2023-07-12
WO2018214929A1 (zh) 2018-11-29
US20210284630A1 (en) 2021-09-16
US11299482B2 (en) 2022-04-12
EP3632909A1 (en) 2020-04-08
CN110650953B (zh) 2023-01-10
ES2955294T3 (es) 2023-11-29
EP3632909A4 (en) 2020-12-23
PT3632909T (pt) 2023-09-27

Similar Documents

Publication Publication Date Title
WO2016184436A1 (zh) 乐伐替尼甲磺酸盐的新晶型及其制备方法
WO2017101847A1 (zh) 吡啶并[1,2-a]嘧啶酮类似物、其晶型、其中间体及其制备方法
WO2023160727A1 (zh) 吲唑类化合物用于治疗银屑病的用途
JP5462268B2 (ja) エポチロングリコシド類化合物とそれを活性成分とする配合物及びその応用
CN111278820B (zh) 一种吡啶酮化合物的晶型、盐型及其制备方法
CN110650953B (zh) 一种穿心莲内酯改构化合物的盐型、晶型及其制备方法
CN114702439A (zh) 一类萘基脲-哌嗪类化合物及其制备方法和应用
CN113354577B (zh) 一种单羰基类姜黄素类化合物及其制备方法与应用
CN114790210A (zh) 一种核苷类化合物盐的晶型
US10815232B2 (en) Crystalline forms of viral-protein inhibitor drug VX-787, processes for preparation thereof and use thereof
CN114685455A (zh) Azd9291结晶固体
JP2022517396A (ja) Ｅｇｆｒ阻害剤の塩、結晶形及びその製造方法
EP4122931A1 (en) Crystalline form of tlr8 agonist
WO2024109937A1 (zh) 一种喹啉胺类化合物的可药用盐、晶型及其制备方法
CN112402412B (zh) 金挖耳内酯化合物在制备治疗炎症引起疾病药物中的应用
CN106995381A (zh) 一种琥珀酸美托洛尔晶型及其制备方法
WO2023143112A1 (zh) 氮杂苯并八元环化合物的盐型、晶型及其应用
EP4365171A1 (en) Crystal form of triazolopyridine-substituted indazole compound and preparation method therefor
CN107007604B (zh) 一种哌啶-溴酚-吲哚酮杂合体化合物在抗肿瘤药物中的应用
CN115403545B (zh) 愈创木烷类倍半萜前药及其用途
JP2019521175A (ja) ニトロイミダゾール系化合物の結晶形、塩形およびその製造方法
CN106397306A (zh) 一种盐酸多奈哌齐晶型化合物及其制备方法
US20150018370A1 (en) Process for the preparation of form III of Vilazodone hydrochloride
JP2024520500A (ja) アニデュラファンギン誘導体の調製方法
CN116585299A (zh) 异甜菊醇氨基醇衍生物在制备抗肿瘤药物中的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant